FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| OMB APPROVAL | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | |
| Estimated average burden | | | | | | | |
| hours per response: | 0.5 | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person STEINMAN LAWRENCE | | | | | | 2. Issuer Name and Ticker or Trading Symbol Pasithea Therapeutics Corp. [KTTA] | | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer Check all applicable) X Director 10% Owner | | | | |
|--|---|--|--|--------------------|--|--|---|--|------|---|--|---|--|---|--|---|---|--|--|
| (Last) (First) (Middle) | | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 11/22/2022 | | | | | | | | | Officer (g below) | | | Other (specify below) | |
| 1111 LINCOLN ROAD, SUITE 500 | | | | 4. If A | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | - 1 | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | |
| (Street) MIAMI BEAC | H FL | 33 | 139 | | | | | | | | | | | X | | • | • | ing Person One Reportin | g Person |
| (City) | (State) | (Zi _l | p) | | | | | | | | | | | | | | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | | |
| Date | | | | | h/Day/Year) | | 2A. Deemed Execution Date, if any (Month/Day/Year) | | | | ies Acquired (A) or Of (D) (Instr. 3, 4 and | | | 5. Amount Securities Beneficiall Following | Folly Owned or Reported (Ir | | nership : Direct (D) direct (I) : 4) | 7. Nature of Indirect Beneficial Ownership | |
| | | | | | | | | | | v | | | (A) or (D) | Price | Transactio (Instr. 3 an | | | | (Instr. 4) |
| Common Stock 11/2 | | | | | | /22/2022 | | | A | | 5,000 |) | A | \$0.99 | 1,282,174 | | | D | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution D if any (Month/Day/ | ate, Year) _ | Code (In 8) | ransaction Der Second (Instr. According to Line 1997) | | | Date | | te Secur ear) Deriva | | Title and Amount of scurities Underlying errivities Security str. 3 and 4) Amount or Number of Shares | | 8. Price of Derivative Security (Instr. 5) | | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |

Explanation of Responses:

/s/ Larry Steinman

11/22/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).